US-based Covidien has launched its next-generation Trellis peripheral infusion system, a pharmacomechanical thrombolysis device that enables focused treatment of blood clots that lead to post-thrombotic syndrome (PTS).
The company has redesigned the Trellis peripheral infusion system to improve thrombus isolation, lytic drug delivery, and removal of dissolved blood clot.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The new device allows clinicians to dissolve acute thrombus and intervene on deep vein thrombosis (DVT) before it advances to PTS.
Trellis peripheral infusion system includes an over-the-wire catheter with two occlusive balloons to close off the treatment area and block drug release to other areas of the body, as well as an infusion zone to deliver the lytic drug and an oscillation drive unit that disperses the drug to dissolve the clot.
Covidien said that the redesigned Trellis system features enhanced drug delivery and increased amplitude of dispersion wire to better distribute the drug throughout the clot.
In addition, the new system has a larger aspiration window than the previous version, which allows for better removal of the drug and the dissolved clot.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataCovidien Vascular Therapies chief medical officer Mark Turco said: "Intervening in patients with DVT may help improve long-term outcomes in a population that can suffer significant complications if left untreated."
At present, the Trellis peripheral infusion system is available in the US, Europe and Canada.
